Palmer, TimWallace, LynnPollock, Kevin G.Cuschieri, KateRobertson, ChrisKavanagh, KimCruickshank, Margaret2019-05-072019-05-072019-04-03Palmer, T, Wallace, L, Pollock, K G, Cuschieri, K, Robertson, C, Kavanagh, K & Cruickshank, M 2019, 'Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland : retrospective population study', BMJ (Clinical research ed.), vol. 365, l1161. https://doi.org/10.1136/bmj.l11610959-8146PubMedCentral: PMC6446188Mendeley: bf0de869-08be-3a40-8dbb-c7db06c0b3f6ORCID: /0000-0002-8893-8620/work/102132276http://hdl.handle.net/2164/12241The manuscript was reviewed by Jo’s Trust, which supports the conclusions. It made the following statement: We think (it has) massive implications for the screening programme, vaccine and also impact on diagnoses in the future. It gives weight for activity to increase vaccine uptake, has implications on screening intervals. The clinically relevant herd protection is very interesting too. It also feeds into our policy calls for a new IT infrastructure (for the screening programme in England) to record and enable invitations based on whether someone has at the vaccine if intervals can be extended. Funding: This study has been undertaken as part of the programme of surveillance of immunisation against human papillomavirus in Scotland, included within the routine work of Health Protection Scotland, a part of the Scottish National Health Service. No funding has been received from industry.10495243engSDG 3 - Good Health and Well-beingABNORMALITIESAUSTRALIACOVERAGECYTOLOGYHUMAN-PAPILLOMAVIRUS VACCINATIONIMPACTLESIONSPROGRAMREDUCTIONWOMENR Medicine (General)General MedicineSupplementary DataR1Journal article10.1136/bmj.l1161http://www.scopus.com/inward/record.url?scp=85063958687&partnerID=8YFLogxKhttp://www.mendeley.com/research/prevalence-cervical-disease-age-20-after-immunisation-bivalent-hpv-vaccine-age-1213-scotland-retrosp365